Dr. Milton H. Werner is founder, president and CEO of Inhibikase Therapeutics, Inc.; adjunct full professor in the School of Biology at the Georgia Institute of Technology; and member of the Winship Cancer Institute of Emory University. Dr. Werner received his PhD in chemistry from the University of California, Berkeley and trained at the National Institutes of Health before joining the Rockefeller University as a head of laboratory in 1996, where he ran a multi-disciplinary research program until 2007.
In 2008, Dr. Werner founded Inhibikase Therapeutics, developing novel treatments for infections and neurodegenerative disorders of the central nervous system, including Parkinson's disease. He is the author of more than 70 research articles, reviews and book chapters and has lectured throughout the world on his research. He is the recipient of numerous private and public research grants totaling more than $14 million. Dr. Werner is the recipient of several awards, including the Young Investigator Award from the Sidney Kimmel Cancer Foundation and a $1 million Young Investigator Award from the W. M. Keck Foundation.